Dihydroartemisinin induces autophagy by suppressing NF-κB activation

Cancer Letters

Volumn 343, Issue 2, 2014, Pages 239-248

  Hu, Wei ^a   Chen, Sang Sang ^a   Zhang, Jia Li ^a   Lou, Xiao E ^a   Zhou, Hui Jun ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Autophagy; Dihydroartemisinin; NF B; ROS; Translocation

Indexed keywords

DIHYDROARTEMISININ; FERRITIN; FERRITIN HEAVY CHAIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; CANCER CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SENSITIZATION; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN TRANSPORT; TRANSCRIPTION REGULATION;

4-HYDROXY-TEMPO; ACIDIC VESICULAR ORGANELLES; ACRIDINE ORANGE; AO; AUTOPHAGY; AVOS; CHLOROQUINE; CQ; DHA; DHE; DIHYDROARTEMISININ; DIHYDROETHIDIUM; FERRITIN HEAVY CHAIN; FHC; INHIBITORY SUBUNIT OF NF-ΚB; IΚB; MANGANESE SUPEROXIDE DISMUTASE; MNSOD; NF-ΚB; NUCLEAR FACTOR-KAPPA B; REACTIVE OXYGEN SPECIES; ROS; TEMPO; TNF-Α; TRANSLOCATION; TUMOR NECROSIS FACTOR-Α;

ANTINEOPLASTIC AGENTS; ARTEMISININS; AUTOPHAGY; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; NF-KAPPA B;

EID: 84891825797     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.035     Document Type: Article

References (48)

1. Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717-1721.
2. Seglen P.O., Bohley P. Autophagy and other vacuolar protein degradation mechanisms. Experientia 1992, 48:158-172.
3. Rubinsztein D.C., Gestwicki J.E., Murphy L.O., Klionsky D.J. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007, 6:304-312.
4. Tsukada M., Ohsumi Y. Isolation and characterization of autophagy-defective mutants of Saccharomyces cerevisiae. FEBS Lett 1993, 333:169-174.
5. Klionsky D.J., Cregg J.M., Dunn W.A., Emr S.D., Sakai Y., Sandoval I.V., Sibirny A., Subramani S., Thumm M., Veenhuis M., Ohsumi Y. A unified nomenclature for yeast autophagy-related genes. Dev. Cell 2003, 5:539-545.
6. Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nat. Rev. Mol. Cell. Biol. 2001, 2:211-216.
7. Alva A.S., Gultekin S.H., Baehrecke E.H. Autophagy in human tumors: cell survival or death?. Cell Death Differ 2004, 11:1046-1048.
8. Kroemer G., Jaattela M. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 2005, 5:886-897.
9. Baehrecke E.H. Autophagy: dual roles in life and death?. Nat. Rev. Mol. Cell Biol. 2005, 6:505-510.
10. Kondo Y., Kanzawa T., Sawaya R., Kondo S. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 2005, 5:726-734.
11. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat. Rev. Cancer 2007, 7:961-967.
12. Marx J. Autophagy: is it cancer's friend or foe?. Science 2006, 312:1160-1161.
13. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J. Clin. Invest. 2001, 107:241-246.
14. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
15. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 1998, 16:225-260.
16. Baeuerle P.A., Henkel T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 1994, 12:141-179.
17. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 2002, 3:221-227.
18. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6910-6924.
19. Bours V., Dejardin E., Goujon-Letawe F., Merville M.P., Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem. Pharmacol. 1994, 47:145-149.
20. Orlowski R.Z., Baldwin A.S. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 2002, 8:385-389.
21. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228:1049-1055.
22. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr. Drug Targets 2006, 7:407-421.
23. Lai H., Sasaki T., Singh N.P., Messay A. Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci. 2005, 76:1267-1279.
24. Chen H., Sun B., Pan S., Jiang H., Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs 2009, 20:131-140.
25. Hou J., Wang D., Zhang R., Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res. 2008, 14:5519-5530.
26. Taylor W.R., White N.J. Antimalarial drug toxicity: a review. Drug Saf. 2004, 27:25-61.
27. Efferth T., Sauerbrey A., Olbrich A., Gebhart E., Rauch P., Weber H.O., Hengstler J.G., Halatsch M.E., Volm M., Tew K.D., Ross D.D., Funk J.O. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol. 2003, 64:382-394.
28. Wu G.D., Zhou H.J., Wu X.H. Apoptosis of human umbilical vein endothelial cells induced by artesunate. Vascul. Pharmacol. 2004, 41:205-212.
29. Zhou H.J., Zhang J.L., Li A., Wang Z., Lou X.E. Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro. Cancer Chemother. Pharmacol. 2010, 66:21-29.
30. Wu X.H., Zhou H.J., Lee J. Dihydroartemisinin inhibits angiogenesis induced by multiple myeloma RPMI8226 cells under hypoxic conditions via downregulation of vascular endothelial growth factor expression and suppression of vascular endothelial growth factor secretion. Anticancer Drugs 2006, 17:839-848.
31. Goujon C., Jarrosson-Wuilleme L., Bernaud J., Rigal D., Darlix J.L., Cimarelli A. Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells. J. Virol. 2003, 77:9295-9304.
32. Mizushima N., Yamamoto A., Matsui M., Yoshimori T., Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol. Biol. Cell 2004, 15:1101-1111.
33. Mizushima N. Methods for monitoring autophagy. Int. J. Biochem. Cell Biol. 2004, 36:2491-2502.
34. Xie Z., Klionsky D.J. Autophagosome formation: core machinery and adaptations. Nat. Cell Biol. 2007, 9:1102-1109.
35. Paglin S., Hollister T., Delohery T., Hackett N., McMahill M., Sphicas E., Domingo D., Yahalom J. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001, 61:439-444.
36. Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
37. Sarkar F.H., Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci. 2008, 13:2950-2959.
38. Sakon S., Xue X., Takekawa M., Sasazuki T., Okazaki T., Kojima Y., Piao J.H., Yagita H., Okumura K., Doi T., Nakano H. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J. 2003, 22:3898-3909.
39. Pham C.G., Bubici C., Zazzeroni F., Papa S., Jones J., Alvarez K., Jayawardena S., De Smaele E., Cong R., Beaumont C., Torti F.M., Torti S.V., Franzoso G. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004, 119:529-542.
40. Djavaheri-Mergny M., Javelaud D., Wietzerbin J., Besancon F. NF-kappaB activation prevents apoptotic oxidative stress via an increase of both thioredoxin and MnSOD levels in TNFalpha-treated Ewing sarcoma cells. FEBS Lett. 2004, 578:111-115.
41. Mayo M.W., Baldwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim. Biophys. Acta 2000, 1470:M55-M62.
42. Webster G.A., Perkins N.D. Transcriptional cross talk between NF-kappaB and p53. Mol. Cell Biol. 1999, 19:3485-3495.
43. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265:956-959.
44. Luo J.L., Kamata H., Karin M. IKK/NF-kappaB signaling: balancing life and death - a new approach to cancer therapy. J. Clin. Invest. 2005, 115:2625-2632.
45. Kim S.J., Kim M.S., Lee J.W., Lee C.H., Yoo H., Shin S.H., Park M.J., Lee S.H. Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro. J. Cancer Res. Clin. Oncol. 2006, 132:129-135.
46. Kern J.C., Kehrer J.P. Free radicals and apoptosis: relationships with glutathione, thioredoxin, and the BCL family of proteins. Front Biosci. 2005, 10:1727-1738.
47. Curtin J.F., Donovan M., Cotter T.G. Regulation and measurement of oxidative stress in apoptosis. J. Immunol. Methods 2002, 265:49-72.
48. Torti F.M., Torti S.V. Regulation of ferritin genes and protein. Blood 2002, 99:3505-3516.